Tracers / [177Lu]Lu-LW02080

[177Lu]Lu-LW02080

Also written as [Lu-177]Lu-LW02080
Radionuclide
Lu-177 t½ 9584.6 min
Modality
Therapy
Production route
—
Stage
preclinical study
Syntheses indexed
1
Preclinical only, no clinical indication yet

What it is

Compound class
DOTA-conjugated bombesin(6-14) antagonist peptide (GRPR-targeted)
Target / mechanism
Gastrin-releasing peptide receptor (GRPR) antagonist PMID 40006047
Clinical application
—
Theranostic pair
<a href="/tracers/ga68-lw02080/">ga68-lw02080</a>

Regulatory status

FDA
—
EMA (centralised)
—
Other approvals
—
Brand names
—

Clinical use

Typical injected activity
—
Uptake time
—

Reported in the literature. Not a dosing recommendation.

Published syntheses

ModuleCassettePurificationYield %RCP %Precursor / supplierSource
Manual synthesiscustom manifoldHPLC+SPE36–64%
yes
>97%LW02080 (DOTA-conjugated peptide)40006047
2025 Pharmaceuticals (Basel)
177LuCl3 (994–2240 MBq) was added into a 4 mL glass vial preloaded with 0.7 mL of NaOAc buffer (0.1 M, pH 4.5) and 10 μL precursor solution (1 mM) and incubated at 95 °C for 15 min with a heating block. — 177Lu-labeled LW02060 and LW02080 were obtained in 36–64% decay-corrected radiochemical yields with >125 GBq/µmol molar activity and >97% radiochemical purity

Need this precursor?We can point you to suppliers for [177Lu]Lu-LW02080, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 40006047. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 40006047: 'LW02080 (DOTA-conjugated peptide)'. Stage set/updated at stage 23 from PMID 40006047: 'PET imaging, SPECT imaging, and ex vivo biodistribution studies were conducted in PC-3 tumor-bearing mice.'.